Idorsia Pharmaceuticals Ltd is a start-up pharmaceutical company headquartered in Basel, Switzerland.

In 2018 I relocated to Basel to join Idorsia’s Editorial Group and worked there for two years as a permanent employee. I returned to the UK in 2020 and continue to support the Editorial Group on a freelance basis.

In that time I’ve edited, proofread and published hundreds of regulatory documents about Idorsia’s drug development, ensuring that all external communications submitted to international health authorities are aligned with the company style, consistently presented and compliant with industry regulations.

I’ve collaborated with authors at different seniority levels across the business and project managed the lifecycle of documents, ensuring we meet pressing deadlines and adhere to stringent pharmaceutical regulations. As Idorsia develops, I’ve also contributed to the company’s evolving brand voice and helped to refine the house Style Guide.

Documents are typically 100+ pages long, written in US English and include technical scientific content. In 2021 the company submitted its first drug application to the FDA and EMA, to treat insomnia in adults and in January 2022, the FDA approved Quviviq – a huge milestone for both the business and patients suffering with insomnia. I contributed to the editing of over 2,000 documents for these submissions.